Myriad Genetics Inc (MYGN) Q3 2026 Earnings Call Highlights: Revenue Guidance Raised as ...
Myriad Genetics Inc (MYGN) lifted its FY2026 revenue midpoint to $785 million and agreed to sell its prenatal health business to LabCorp for $210 million, even as Q3 revenue slipped 1% year-over-year. Related Stocks: MYGN ,